OTCMKTS:ECTE Echo Therapeutics (ECTE) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 09/7/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Echo Therapeutics Stock (OTCMKTS:ECTE) Get Echo Therapeutics alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.28VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Echo Therapeutics Inc. is a developer of non‐invasive biosensing platforms, with a particular focus on continuous glucose monitoring for diabetes management. The company’s core technology utilizes reverse iontophoresis to extract interstitial fluid through the skin, enabling real‐time glucose measurements without the need for fingerstick blood tests. Over its history, Echo Therapeutics has sought FDA clearance for wearable monitoring devices designed to deliver actionable data to patients and healthcare providers. Echo Therapeutics’ first commercial product, the GlucoWatch® Biographer, received FDA approval in the early 2000s and represented one of the initial attempts to bring transdermal glucose sensing to market. Although the company faced regulatory and market challenges with its first‐generation device, it continued to refine its sensing platform through research collaborations and strategic partnerships. Echo Therapeutics has historically been based in the United States and has pursued distribution and reimbursement pathways in North America and select international markets. Building on its proprietary transdermal sensing technology, Echo Therapeutics is exploring applications beyond glucose monitoring, including pharmacokinetic studies and adherence tracking for a variety of therapeutic areas. While information on its current product pipeline and executive team is limited, the company remains focused on advancing minimally invasive diagnostic solutions. Echo Therapeutics trades on the OTC Markets under the symbol ECTE, where it engages with investors regarding its ongoing research and development efforts.AI Generated. May Contain Errors. Read More Receive ECTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Echo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ECTE Stock News HeadlinesECTE/BTC - EurocoinToken BitcoinAugust 30, 2024 | investing.comWhat are echo chambers?December 9, 2023 | bbc.co.ukBUY THIS: Claim a backdoor stake in SpaceXMarc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade available in your brokerage account today that offers backdoor pre-IPO exposure to SpaceX. With the IPO date approaching, Chaikin believes this position could benefit from as high as a $122 billion windfall on IPO day - and he warns against buying in on day one due to potential price instability.June 18 at 1:00 AM | Chaikin Analytics (Ad)ECTE/USD Synthetic Historical DataDecember 3, 2023 | investing.comECTE Historical DataOctober 18, 2023 | investing.comBest Smart Speakers for 2023: We Tested Alexa, Google, Apple and MoreJuly 11, 2023 | cnet.comIn echo of Jan. 6 attack in U.S., Brazilian protesters storm their Congress, high court and palaceJanuary 11, 2023 | usatoday.comNow is the time to buy an Echo Dot smart speaker on Amazon — prices start at just $14.99, and the newest model is under $40!November 28, 2022 | yahoo.comSee More Headlines ECTE Stock Analysis - Frequently Asked Questions How have ECTE shares performed this year? Echo Therapeutics' stock was trading at $0.0002 at the beginning of 2026. Since then, ECTE stock has increased by 0.0% and is now trading at $0.0002. How were Echo Therapeutics' earnings last quarter? Echo Therapeutics Inc. (OTCMKTS:ECTE) posted its earnings results on Friday, August, 12th. The medical device company reported ($0.82) earnings per share for the quarter. How do I buy shares of Echo Therapeutics? Shares of ECTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Echo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Echo Therapeutics investors own include DexCom (DXCM), Athersys (ATHX), Blackstone Strategic Credit 2027 Term Fund (BGB), BlackRock Science and Technology Trust (BST). Company Calendar Last Earnings8/12/2016Today6/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolOTCMKTS:ECTE Previous SymbolNASDAQ:ECTE CIK1031927 Webwww.echotx.com Phone(732) 201-4194Fax215-717-4109Employees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:ECTE) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersBuy now or wait?SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Echo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Echo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.